Evaluation of in Vitro Activity of Ceftazidime/Avibactam and Ceftolozane/Tazobactam against ESBL-producing Enterobacterales Isolated from Intensive Care Units from Qatar

Evaluation of in Vitro Activity of Ceftazidime/Avibactam and Ceftolozane/Tazobactam against ESBL-producing Enterobacterales Isolated from Intensive Care Units from Qatar

Objectives: Extended-spectrum β-lactamases (ESBLs) mechanism of resistance in Enterobacterales leads to poor clinical outcomes. Ceftazidime/avibactam and ceftolozane/tazobactam are two broad-spectrum antimicrobial combinations that are effective against multidrug-resistant organisms with regional va...

Full description

Bibliographic Details
Main Authors:	Mazen A. Sid Ahmed, Emad Bashir Ibrahim, Jemal M. Hamid, Joanne Daghfal, Mohammed A. Alyazidi, Aimen H. Abdelwahab, Muna A. Al-Maslamani, Abdul Latif Al Khal, Hamad Abdel Hadi
Format:	Article
Language:	English
Published:	Oman Medical Specialty Board 2022-09-01
Series:	Oman Medical Journal
Subjects:	enterobacterial beta-lactamase tem-11 antimicrobial drug resistance ceftazidime-avibactam ceftolozane-tazobactam qatar
Online Access:	https://omjournal.org/articleDetails.aspx?coType=1&aId=3188

Similar Items

Evaluation of In Vitro Activity of Ceftolozane-tazobactam and Ceftazidime-avibactam Against Carbapenemase-producing Multi-drug Resistant Klebsiella pneumoniae Isolates
by: Hüseyin Agah TERZİ, et al.
Published: (2020-12-01)

Antimicrobial Activity of Ceftolozane-Tazobactam, Ceftazidime-Avibactam, and Cefiderocol against Multidrug-Resistant Pseudomonas aeruginosa Recovered at a German University Hospital
by: C. Weber, et al.
Published: (2022-10-01)

Combined Resistance to Ceftolozane-Tazobactam and Ceftazidime-Avibactam in Extensively Drug-Resistant (XDR) and Multidrug-Resistant (MDR) <i>Pseudomonas aeruginosa</i>: Resistance Predictors and Impact on Clinical Outcomes Besides Implications for Antimicrobial Stewardship Programs
by: Marianna Meschiari, et al.
Published: (2021-10-01)

Comparison of antimicrobial activity between ceftolozane–tazobactam and ceftazidime–avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa
by: Adnan Alatoom, et al.
Published: (2017-09-01)

Susceptibility of Meropenem-Resistant and/or Carbapenemase-Producing Clinical Isolates of <i>Enterobacterales</i> (<i>Enterobacteriaceae</i>) and <i>Pseudomonas aeruginosa</i> to Ceftazidime-Avibactam and Ceftolozane-Tazobactam as Assessed by In Vitro Testing Methods
by: Venere Cortazzo, et al.
Published: (2022-07-01)

Ceftolozane/Tazobactam and Ceftazidime/Avibactam for Multidrug-Resistant Gram-Negative Infections in Immunocompetent Patients: A Single-Center Retrospective Study
by: Rosario Cultrera, et al.
Published: (2020-09-01)

Evaluation of in-vitro susceptibility of ß-lactam-resistant Gram-negative bacilli to ceftazidime-avibactam and ceftolozane-tazobactam from clinical samples of a general hospital in southern Brazil
by: Thaisa Noceti Carvalho, et al.
Published: (2023-01-01)

Best practices: Appropriate use of the new β-lactam/β-lactamase inhibitor combinations, ceftazidime-avibactam and ceftolozane-tazobactam in South Africa
by: Adrian J. Brink, et al.
Published: (2022-10-01)

Extensively drug-resistant Pseudomonas aeruginosa: clinical features and treatment with ceftazidime/avibactam and ceftolozane/tazobactam in a tertiary care university hospital center in Portugal – A cross-sectional and retrospective observational study
by: Diogo Mendes Pedro, et al.
Published: (2024-02-01)

Susceptibility of multi-drug resistant isolates of Pseudomonas aeruginosa to ceftazidime/aviabactam and ceftolozane/tazobactam in Benha University Hospital in Egypt and detection of carbapenemase genes
by: Sahar Fayed, et al.
Published: (2023-08-01)

SUSCETIBILIDADE DE ISOLADOS DE ENTEROBACTEREALES RESISTENTE AOS CARBAPENÊMICOS AOS ANTIBIÓTICOS CEFTAZIDIMA-AVIBACTAM, CEFTOLOZANE-TAZOBACTAM E CEFIDEROCOL
by: Deise Reis Carvalho, et al.
Published: (2023-10-01)

Association of <i>bla</i><sub>VIM-2</sub>, <i>bla</i><sub>PDC-35</sub>, <i>bla</i><sub>OXA-10,</sub> <i>bla</i><sub>OXA-488</sub> and <i>bla</i><sub>VEB-9</sub> β-Lactamase Genes with Resistance to Ceftazidime–Avibactam and Ceftolozane–Tazobactam in Multidrug-Resistant <i>Pseudomonas aeruginosa</i>
by: Mazen A. Sid Ahmed, et al.
Published: (2022-01-01)

Evaluation of ceftolozane-tazobactam susceptibility on a French nationwide collection of Enterobacterales
by: Agnès B. Jousset, et al.
Published: (2023-03-01)

In vitro effectiveness of ceftazidime-avibactam in combination with aztreonam on carbapenemase-producing Enterobacterales
by: Papa-Ezdra Romina, et al.
Published: (2023-12-01)

Drug Regimens of Novel Antibiotics in Critically Ill Patients with Varying Renal Functions: A Rapid Review
by: Julie Gorham, et al.
Published: (2022-04-01)

Rationale and evidence for the use of new beta-lactam/beta-lactamase inhibitor combinations and cefiderocol in critically ill patients
by: François Barbier, et al.
Published: (2023-07-01)

Carbapenem-resistant Pseudomonas aeruginosa: an assessment of frequency of isolation from ICU versus non-ICU, phenotypic and genotypic profiles in a multinational population of hospitalized patients
by: Christian M. Gill, et al.
Published: (2022-11-01)

Acetylcysteine increases sensitivity of ceftazidime-avibactam–resistant enterobacterales with different enzymatic resistance to ceftazidime-avibactam in vitro and in vivo
by: Zeyu Huang, et al.
Published: (2023-11-01)

Ceftazidime-avibactam susceptibility among KPC-producing enterobacterales in southern Brazil
by: Natália Kehl Moreira, et al.
Published: (2023-11-01)

The <i>Klebsiella pneumoniae</i> carbapenemase (KPC) β-Lactamase Has Evolved in Response to Ceftazidime Avibactam
by: Sona Garsevanyan, et al.
Published: (2023-12-01)

Use of Newer and Repurposed Antibiotics against Gram-Negative Bacteria in Neonates
by: Angeliki Kontou, et al.
Published: (2023-06-01)

The Role of Colistin in the Era of New β-Lactam/β-Lactamase Inhibitor Combinations
by: Abdullah Tarık Aslan, et al.
Published: (2022-02-01)

Multicentre Evaluation of the EUCAST Rapid Antimicrobial Susceptibility Testing (RAST) Extending Analysis to 16–20 Hours Reading Time
by: Gabriele Bianco, et al.
Published: (2022-10-01)

Satisfactory In Vitro Activity of Ceftolozane<tt>–</tt>Tazobactam against Carbapenem-Resistant <i>Pseudomonas aeruginosa</i> But Not against <i>Klebsiella pneumoniae</i> Isolates
by: Alicja Sękowska, et al.
Published: (2023-03-01)

Subgroup analysis of phase 2 study of ceftolozane/tazobactam in neonates and young infants with pyelonephritis
by: Emmanuel Roilides, et al.
Published: (2023-10-01)

A Selective Medium for Screening Ceftazidime/Avibactam Resistance in Carbapenem-Resistant Enterobacterales
by: Weiliang Zeng, et al.
Published: (2022-07-01)

Comparison between meropenem and ceftolozane/tazobactam: possible influence of CRRT
by: Patrick M. Honore, et al.
Published: (2022-01-01)

A phase III, multicenter, double-blind, randomized clinical trial to evaluate the efficacy and safety of ceftolozane/tazobactam plus metronidazole versus meropenem in Chinese participants with complicated intra-abdominal infections
by: Yihong Sun, et al.
Published: (2022-10-01)

Cost-effectiveness of ceftolozane/tazobactam for the treatment of complicated intraabdominal and urinary tract infections in Colombia
by: Fabián Hernández
Published: (2020-02-01)

What to Do with the New Antibiotics?
by: Khalil Chaïbi, et al.
Published: (2023-03-01)

Tazobactam/ceftolozane and tobramycin combination therapy in extensively drug-resistant Pseudomonas aeruginosa infections in severe burn injury: a case report
by: Yuta Ibe, et al.
Published: (2023-08-01)

Activity of Ceftolozane-Tazobactam Against Gram-Negative Isolates from Australia and New Zealand as part of the PACTS Surveillance 2016-2018
by: Dee Shortridge, et al.
Published: (2022-12-01)

Use of Ceftolozane/Tazobactam for the Treatment of Multidrug-Resistant <i>Pseudomonas aeruginosa</i> Pneumonia in a Pediatric Patient with Combined Immunodeficiency (CID): A Case Report from a Tertiary Hospital in Saudi Arabia
by: Ahmed Zikri, et al.
Published: (2019-05-01)

XDR-<i>Pseudomonas aeruginosa</i> Outside the ICU: Is There Still Place for Colistin?
by: Paola Del Giacomo, et al.
Published: (2022-02-01)

In Vitro Activity of Newer and Conventional Antimicrobial Agents, Including Fosfomycin and Colistin, against Selected Gram-Negative Bacilli in Kuwait
by: Wadha Alfouzan, et al.
Published: (2018-09-01)

Treatment of multidrug-resistant Pseudomonas aeruginosa bacteremia using ceftolozane-tazobactam-based or colistin-based antibiotic regimens: A multicenter retrospective study
by: Hakeam A. Hakeam, et al.
Published: (2022-10-01)

In Vitro Activity of Ceftolozane-Tazobactam and Other Antibiotics against <i>Pseudomonas aeruginosa</i> Infection-Isolates from an Academic Medical Center in Thailand
by: Woraphot Tantisiriwat, et al.
Published: (2022-05-01)

In Vitro Activities of Ceftazidime–Avibactam and Aztreonam–Avibactam at Different Inoculum Sizes of Extended-Spectrum β-Lactam-Resistant Enterobacterales Blood Isolates
by: Moonsuk Bae, et al.
Published: (2021-12-01)

Ceftazidime–Avibactam Improves Outcomes in High-Risk Neutropenic Patients with <i>Klebsiella pneumoniae</i> Carbapenemase-Producing Enterobacterales Bacteremia
by: Fabián Herrera, et al.
Published: (2024-01-01)

Temporal and geographical prevalence of carbapenem-resistant Pseudomonas aeruginosa and the in vitro activity of ceftolozane/tazobactam and comparators in Taiwan—SMART 2012–2021
by: James A. Karlowsky, et al.
Published: (2023-09-01)